Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure

doi:10.4239/wjd.v14.i9.1385

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1862)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

929

Figures (1-4)

164

Tables (1-3)

202

Sum=1358

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

119

Download

279

Sum=398

Sep 15, 2023 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Sep 15, 2023; 14(9): 1385-1392
Published online Sep 15, 2023. doi: 10.4239/wjd.v14.i9.1385

Full Size Figure Download Figure

Figure 3 Least absolute shrinkage and selection operator-based screening of predictors. A, B: The coefficient distribution of the least absolute shrinkage and selection operator repression analysis and the calculation of adjustment parameters (lambda) based on partial likelihood deviation of 10 times cross-validation.

Citation: Ma XY, Sheng YP, Yang XM, Zhang HR, Sun FY. Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure. World J Diabetes 2023; 14(9): 1385-1392
URL: https://www.wjgnet.com/1948-9358/full/v14/i9/1385.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i9.1385